COG1

Summary

COG1 (component of oligomeric golgi complex 1, HGNC:6545) is a protein-coding gene on chromosome 17q25.1, encoding Conserved oligomeric Golgi complex subunit 1 (Q8WTW3). Required for normal Golgi function. It is a selective cancer dependency (DepMap: 52.8% of cell lines).

The protein encoded by this gene is one of eight proteins (Cog1-8) which form a Golgi-localized complex (COG) required for normal Golgi morphology and function. It is thought that this protein is required for steps in the normal medial and trans Golgi-associated processing of glycoconjugates and plays a role in the organization of the Golgi-localized complex.

Source: NCBI Gene 9382 — RefSeq curated summary.

At a glance

• Gene–disease (curated): COG1-congenital disorder of glycosylation (Definitive, GenCC)
• Clinical variants (ClinVar): 519 total — 14 pathogenic, 7 likely-pathogenic (top 6% of genes corpus-wide)
• GTEx eGene: eQTL in 19 tissues, sQTL in 18 (q < 0.05)
• Phenotypes (HPO): 91
• Cancer dependency (DepMap): dependent in 52.8% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity unscored
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.72 (unconstrained)
• MANE Select transcript: NM_018714

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6545
Approved symbol	COG1
Name	component of oligomeric golgi complex 1
Location	17q25.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1381
Ensembl gene	ENSG00000166685
Ensembl biotype	protein_coding
OMIM	606973
Entrez	9382

Gene structure

Transcript identifiers

Ensembl transcripts: 34 — 18 nonsense_mediated_decay, 13 protein_coding, 3 retained_intron

MANE Select: ENST00000299886

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 4, TSL 3: 3

ENST00000299886, ENST00000438720, ENST00000577238, ENST00000577844, ENST00000580271, ENST00000582512, ENST00000582587, ENST00000582672, ENST00000582973, ENST00000876963, ENST00000876964, ENST00000876965, ENST00000923183, ENST00000947884, ENST00000947885, ENST00000992734, ENST00000992735, ENST00000992736, ENST00001025276, ENST00001025277, ENST00001025280, ENST00001025281, ENST00001025282, ENST00001025284, ENST00001025285, ENST00001079998, ENST00001109060, ENST00001109061, ENST00001109062, ENST00001109063, ENST00001109064, ENST00001113514, ENST00001123559, ENST00001141917

RefSeq mRNA: 1 — MANE Select: NM_018714 NM_018714

CCDS: CCDS11692

Canonical transcript exons

ENST00000299886 — 14 exons

Exon	Start	End
ENSE00001105601	73206708	73206817
ENSE00001105604	73197226	73197396
ENSE00001105614	73196507	73196751
ENSE00001105619	73203632	73203793
ENSE00001105631	73201109	73201900
ENSE00001105640	73205553	73205680
ENSE00001105647	73203000	73203146
ENSE00001105651	73196900	73197081
ENSE00001136834	73200566	73200776
ENSE00001136838	73199865	73200021
ENSE00002719633	73193055	73193384
ENSE00003501326	73207181	73207256
ENSE00003525871	73206154	73206262
ENSE00003601993	73208314	73208507

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 95.76.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.9904 / max 128.3385, expressed in 1810 samples.

Highest expression (Bgee): hemisphere of cerebellum, cerebellar hemisphere, apex of heart, cerebellar cortex, frontal lobe.

Genetic regulation across tissues (GTEx eQTL / sQTL)

COG1 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 19 tissues and its splicing (sQTL) in 18 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 37 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	eqtl	4.2e-22	+0.49	17:73193924:C:T
Thyroid	eqtl	4.0e-18	+0.28	17:73218354:T:C
Cells Cultured fibroblasts	eqtl	3.0e-17	+1.08	17:73198466:G:T
Muscle Skeletal	eqtl	4.9e-17	+0.23	17:73256884:G:A
Whole Blood	eqtl	7.7e-17	-0.16	17:73192144:C:T
Brain Frontal Cortex BA9	sqtl	1.8e-15	-1.91	17:73205817:G:A
Brain Nucleus accumbens basal ganglia	sqtl	2.9e-13	-2.06	17:73198067:G:GC
Brain Caudate basal ganglia	sqtl	3.2e-11	-1.59	17:73194333:C:T
Brain Cortex	sqtl	1.9e-10	-1.57	17:73198067:G:GC
Brain Anterior cingulate cortex BA24	sqtl	5.5e-09	+1.91	17:73181564:G:A
Esophagus Mucosa	eqtl	6.9e-09	+0.20	17:73179889:G:A
Brain Putamen basal ganglia	sqtl	1.3e-08	-1.89	17:73223884:A:G
Brain Cerebellum	sqtl	1.7e-07	-1.02	17:73205817:G:A
Pancreas	eqtl	5.9e-07	+0.21	17:73256884:G:A
Brain Cerebellar Hemisphere	sqtl	2.4e-06	-0.65	17:73205817:G:A
Heart Atrial Appendage	eqtl	2.1e-05	-0.20	17:73192144:C:T
Heart Left Ventricle	eqtl	2.2e-05	-0.13	17:73192144:C:T
Testis	sqtl	2.2e-05	-1.01	17:73205817:G:A
Brain Frontal Cortex BA9	eqtl	3.4e-05	+0.18	17:73218611:G:A
Brain Cortex	eqtl	4.2e-05	+0.18	17:73218611:G:A

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
162563	22.9904	1810

Top tissues by expression

showing 100 of 260 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	95.76	gold quality
cerebellar hemisphere	UBERON:0002245	95.68	gold quality
apex of heart	UBERON:0002098	95.64	gold quality
cerebellar cortex	UBERON:0002129	95.59	gold quality
right frontal lobe	UBERON:0002810	95.05	gold quality
cerebellum	UBERON:0002037	95.00	gold quality
adenohypophysis	UBERON:0002196	94.91	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.83	gold quality
nucleus accumbens	UBERON:0001882	94.69	gold quality
pituitary gland	UBERON:0000007	94.54	gold quality
prefrontal cortex	UBERON:0000451	94.34	gold quality
anterior cingulate cortex	UBERON:0009835	94.25	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.00	gold quality
caudate nucleus	UBERON:0001873	93.83	gold quality
body of pancreas	UBERON:0001150	93.72	gold quality
heart left ventricle	UBERON:0002084	93.70	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.61	gold quality
gastrocnemius	UBERON:0001388	93.55	gold quality
right uterine tube	UBERON:0001302	93.54	gold quality
amygdala	UBERON:0001876	93.48	gold quality
putamen	UBERON:0001874	93.35	gold quality
cardiac ventricle	UBERON:0002082	93.30	gold quality
frontal cortex	UBERON:0001870	93.27	gold quality
frontal lobe	UBERON:0016525	93.27	gold quality
muscle of leg	UBERON:0001383	93.08	gold quality
endocervix	UBERON:0000458	92.99	gold quality
neocortex	UBERON:0001950	92.95	gold quality
right ovary	UBERON:0002118	92.90	gold quality
left ovary	UBERON:0002119	92.69	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.48	gold quality
transverse colon	UBERON:0001157	92.40	gold quality
forebrain	UBERON:0001890	92.39	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.31	gold quality
brain	UBERON:0000955	92.30	gold quality
body of uterus	UBERON:0009853	92.28	gold quality
right atrium auricular region	UBERON:0006631	92.26	gold quality
left adrenal gland cortex	UBERON:0035825	92.25	gold quality
left adrenal gland	UBERON:0001234	92.20	gold quality
hypothalamus	UBERON:0001898	92.18	gold quality
metanephros cortex	UBERON:0010533	92.17	gold quality
cerebral cortex	UBERON:0000956	92.16	gold quality
rectum	UBERON:0001052	92.14	gold quality
tibialis anterior	UBERON:0001385	92.14	silver quality
right adrenal gland cortex	UBERON:0035827	92.14	gold quality
right adrenal gland	UBERON:0001233	92.03	gold quality
body of stomach	UBERON:0001161	92.02	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.00	gold quality
lower esophagus	UBERON:0013473	91.99	gold quality
mucosa of transverse colon	UBERON:0004991	91.95	gold quality
heart	UBERON:0000948	91.88	gold quality
cardiac atrium	UBERON:0002081	91.87	gold quality
mucosa of stomach	UBERON:0001199	91.86	gold quality
right lobe of thyroid gland	UBERON:0001119	91.78	gold quality
tibial nerve	UBERON:0001323	91.78	gold quality
ectocervix	UBERON:0012249	91.75	gold quality
left lobe of thyroid gland	UBERON:0001120	91.72	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	91.71	gold quality
adrenal cortex	UBERON:0001235	91.69	gold quality
pancreas	UBERON:0001264	91.67	gold quality
popliteal artery	UBERON:0002250	91.64	gold quality
tibial artery	UBERON:0007610	91.64	gold quality
adrenal gland	UBERON:0002369	91.43	gold quality
kidney epithelium	UBERON:0004819	91.43	silver quality
Ammon’s horn	UBERON:0001954	91.39	gold quality
skin of leg	UBERON:0001511	91.36	gold quality
islet of Langerhans	UBERON:0000006	91.32	gold quality
left ventricle myocardium	UBERON:0006566	91.31	silver quality
temporal lobe	UBERON:0001871	91.29	gold quality
stromal cell of endometrium	CL:0002255	91.24	gold quality
aorta	UBERON:0000947	91.21	gold quality
lower esophagus mucosa	UBERON:0035834	91.21	gold quality
smooth muscle tissue	UBERON:0001135	91.16	gold quality
thyroid gland	UBERON:0002046	91.15	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	90.92	gold quality
minor salivary gland	UBERON:0001830	90.88	gold quality
right lung	UBERON:0002167	90.87	gold quality
right coronary artery	UBERON:0001625	90.86	gold quality
ascending aorta	UBERON:0001496	90.81	gold quality
small intestine	UBERON:0002108	90.80	gold quality
thoracic aorta	UBERON:0001515	90.78	gold quality
left uterine tube	UBERON:0001303	90.74	gold quality
colon	UBERON:0001155	90.72	gold quality
descending thoracic aorta	UBERON:0002345	90.69	gold quality
left coronary artery	UBERON:0001626	90.58	gold quality
deltoid	UBERON:0001476	90.57	silver quality
spleen	UBERON:0002106	90.57	gold quality
large intestine	UBERON:0000059	90.47	gold quality
intestine	UBERON:0000160	90.41	gold quality
stomach	UBERON:0000945	90.41	gold quality
uterine cervix	UBERON:0000002	90.34	gold quality
skin of abdomen	UBERON:0001416	90.29	gold quality
granulocyte	CL:0000094	90.28	gold quality
fundus of stomach	UBERON:0001160	90.25	gold quality
right lobe of liver	UBERON:0001114	90.24	gold quality
subcutaneous adipose tissue	UBERON:0002190	90.24	gold quality
coronary artery	UBERON:0001621	90.13	gold quality
ovary	UBERON:0000992	90.05	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.01	gold quality
prostate gland	UBERON:0002367	89.99	gold quality
sural nerve	UBERON:0015488	89.94	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.71
E-MTAB-10137	no	516.06

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Nucleus accumbens	tissue	49.9
Hippocampus	tissue	46.5	medium
Postcentral gyrus	tissue	46.0
Skeletal muscle	tissue	38.9	medium
Locus coeruleus	tissue	37.1
Cerebral cortex	tissue	36.3	medium
Somatosensory cortex	tissue	36.3
Tongue	tissue	33.2
Pituitary gland	tissue	32.3
Thalamus	tissue	32.2
Heart muscle	tissue	31.2	low
Occipital cortex	tissue	30.6
Superior colliculi	tissue	30.3
Motor cortex	tissue	30.2
Hippocampal formation	tissue	30.2
Choroid plexus	tissue	29.8
Cerebellum	tissue	28.9	high
Midbrain	tissue	28.8
Caudate putamen	tissue	28.5
Prefrontal cortex	tissue	28.3
Pons	tissue	28.2
Temporal cortex	tissue	27.8
Medulla oblongata	tissue	27.7
Hypothalamus	tissue	27.3
Entorhinal cortex	tissue	27.2
Retrosplenial and cingulate cortex	tissue	26.9
Substantia nigra	tissue	26.5
Retrosplenial cortex	tissue	26.4
Spinal cord	tissue	26.1
Insular cortex	tissue	26.1
Corpus callosum	tissue	25.9
Basal ganglia	tissue	25.3	medium
Frontal cortex	tissue	25.0
Putamen	tissue	25.0
Periaqueductal gray	tissue	25.0
Septum	tissue	25.0
Ventral forebrain	tissue	24.9
Retina	tissue	23.5
Amygdala	tissue	23.5
Pancreas	tissue	21.3	medium
Olfactory bulb	tissue	21.3
Rectum	tissue	18.4	medium
Ovary	tissue	18.0	high
Cervix	tissue	17.8	medium
Salivary gland	tissue	17.8	high
Adrenal gland	tissue	17.8	high
Smooth muscle	tissue	17.6	low
Vagina	tissue	16.7	medium
Parathyroid gland	tissue	16.6	low
Epididymis	tissue	16.6	medium
Seminal vesicle	tissue	16.5	high
Colon	tissue	16.3	high
Fallopian tube	tissue	16.2	high
Endometrium 1	tissue	16.1	high
Duodenum	tissue	15.3	high
Prostate	tissue	15.2	high
Bone marrow	tissue	15.1	high
Testis	tissue	14.9	high
Skin 1	tissue	14.4	medium
Stomach 1	tissue	14.2	medium

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Perirhinal gyrus (67.3), Olfactory area (64.7), Olfactory tubercle (61.2), Nucleus of the diagonal band (60.1), Temporal pole (57.1).

Regulation

Is transcription factor: no

Functional genomics

gnomAD constraint: pLI 6.1e-11, LOEUF 0.718, missense Z 1.13 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000299886 — one region, missense o/e 0.94. ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity Not yet evaluated (unscored). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 52.8% of screened cell lines.

Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): SNB75 (-1.372), 769-P (-1.297), KARPAS-422 (-1.246), SNU-16 (-1.237), OAW42 (-1.237), COV362 (-1.231), 786-O (-1.228), MPP 89 (-1.214), LOU-NH91 (-1.164), KMS-34 (-1.162), RT-112 (-1.153), SU-DHL-10 (-1.145), NCI-H2452 (-1.129), NCI-H2882 (-1.116), huH-1 (-1.077).

Literature-anchored findings (GeneRIF, showing 5)

• Sec34 is implicated in traffic from the endoplasmic reticulum to the Golgi and exists in a complex with GTC-90 and ldlBp (PMID:11929878)
• These findings support the proposal that COG is directly involved in controlling vesicular retrograde transport of Golgi resident proteins throughout the Golgi apparatus. (PMID:16857184)
• A novel mutation in COG1 was found in two patients with a cerebrocostomandibular-like syndrome. (PMID:19008299)
• This study reports a novel set of Dengue virus (DENV) NS1-interacting host cell proteins in the HepG2 cell line and proposes possible roles for human NEK2, TAO1, and COG1 in DENV infection. (PMID:27108190)
• Chronic renal patients with more atherogenic lipoprotein LDL B phenotype are in advanced state of oxidative stress compared with control subjects. (PMID:27412679)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cog1	ENSDARG00000105131
mus_musculus	Cog1	ENSMUSG00000018661
rattus_norvegicus	Cog1	ENSRNOG00000002795
drosophila_melanogaster	Cog1	FBGN0037998
caenorhabditis_elegans	cogc-1	WBGENE00003258

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1333873) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 4 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal embryo implantation	1
abnormal inner cell mass morphology	1
embryonic lethality between implantation and somite formation, complete penetrance	1
preweaning lethality, complete penetrance	1

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
SDK2-AS1	ncRNA	101928251
CDC42EP4	protein-coding	23580
SDK2	protein-coding	54549
MTNAP1	protein-coding	55028
CPSF4L	protein-coding	642843
VCF1	protein-coding	84923
SSTR2	protein-coding	6752
SLC39A11	protein-coding	201266

Protein

Protein identifiers

Conserved oligomeric Golgi complex subunit 1 — Q8WTW3 (reviewed: Q8WTW3)

Alternative names: Component of oligomeric Golgi complex 1

All UniProt accessions (6): Q8WTW3, E9PBL8, J3KRP4, J3KSY3, J3QKY9, J3QLT5

UniProt curated annotations — full annotation on UniProt →

Function. Required for normal Golgi function.

Subunit / interactions. Component of the conserved oligomeric Golgi complex which is composed of eight different subunits and is required for normal Golgi morphology and localization.

Subcellular location. Golgi apparatus membrane.

Disease relevance. Congenital disorder of glycosylation 2G (CDG2G) [MIM:611209] A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Clinical features of CDG2G include failure to thrive, generalized hypotonia, growth retardation and mild psychomotor retardation. CDG2G is biochemically characterized by a defect in O-glycosylation as well as N-glycosylation. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the COG1 family.

RefSeq proteins (1): NP_061184* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR033370	COG1	Family

Pfam: PF08700

UniProt features (7 total): sequence variant 3, modified residue 2, initiator methionine 1, chain 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WTW3-F1	77.82	0.40

Human Protein Atlas

Protein class: Predicted intracellular proteins, Disease related genes, Human disease related genes, Congenital disorders of metabolism, Congenital disorders of glycan/glycoprotein metabolism, Essential proteins

Protein evidence: Evidence at protein level

Antibody reliability (HPA): IH approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2)

Type	Positions
N-acetylalanine	2
Phosphoserine	7

Function

Pathways and Gene Ontology

Reactome pathways

4 curated (TAS) of 12; 1 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

12 pathways:

ID	Pathway	Evidence
R-HSA-9918481	Dengue Virus-Host Interactions ⚕	curated
R-HSA-6807878	COPI-mediated anterograde transport	curated
R-HSA-6811438	Intra-Golgi traffic	curated
R-HSA-6811440	Retrograde transport at the Trans-Golgi-Network	curated
R-HSA-446203	Asparagine N-linked glycosylation	—
R-HSA-199977	ER to Golgi Anterograde Transport	—
R-HSA-6811442	Intra-Golgi and retrograde Golgi-to-ER traffic	—
R-HSA-199991	Membrane Trafficking	—
R-HSA-392499	Metabolism of proteins	—
R-HSA-597592	Post-translational protein modification	—
R-HSA-948021	Transport to the Golgi and subsequent modification	—
R-HSA-5653656	Vesicle-mediated transport	—

MSigDB gene sets: 289 (showing top): GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GOBP_INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT, GOCC_TRANS_GOLGI_NETWORK, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_GOLGI_ORGANIZATION, GOCC_GOLGI_TRANSPORT_COMPLEX, GOCC_TRANS_GOLGI_NETWORK_MEMBRANE, GOCC_ORGANELLE_SUBCOMPARTMENT, GOBP_GOLGI_VESICLE_TRANSPORT, HATADA_METHYLATED_IN_LUNG_CANCER_UP, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION

GO Biological Process (4): retrograde transport, vesicle recycling within Golgi (GO:0000301), intra-Golgi vesicle-mediated transport (GO:0006891), Golgi organization (GO:0007030), protein transport (GO:0015031)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), COG complex (GO:0017119), trans-Golgi network membrane (GO:0032588)

Reactome top-level categories

9 top-level categories:

Category	Pathways
Intra-Golgi and retrograde Golgi-to-ER traffic	2
Membrane Trafficking	2
ER to Golgi Anterograde Transport	1
Dengue Virus Infection	1
Transport to the Golgi and subsequent modification	1
Vesicle-mediated transport	1
Post-translational protein modification	1
Metabolism of proteins	1
Asparagine N-linked glycosylation	1

GO top-level categories

16 GO namespaces:

Category	Terms
Golgi apparatus	2
intra-Golgi vesicle-mediated transport	1
Golgi vesicle transport	1
organelle organization	1
endomembrane system organization	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
binding	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
vesicle tethering complex	1
trans-Golgi network	1
organelle membrane	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 4 of 9 annotations. The rest are phylogenetic / computational / electronic (IEA).

4 experimentally-supported GO terms:

GO term	NS	Evidence
Golgi organization	BP	mutant phenotype
retrograde transport, vesicle recycling within Golgi	BP	mutant phenotype
COG complex	CC	direct assay
Golgi apparatus	CC	direct assay

Protein interactions and networks

STRING

showing 15 of 998 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
COG1	COG2	Q14746	991
COG1	COG3	Q96JB2	984
COG1	COG5	Q9UP83	984
COG1	COG7	P83436	983
COG1	COG8	Q96MW5	964
COG1	COG4	Q9H9E3	945
COG1	COG6	Q9Y2V7	933
COG1	GOSR2	O14653	724
COG1	VPS51	Q9UID3	688
COG1	VPS53	Q5VIR6	666
COG1	VPS54	Q9P1Q0	665
COG1	COPB1	P53618	653
COG1	STX16	O14662	633
COG1	RINT1	Q6NUQ1	630
COG1	STX5	Q13190	629

IntAct

Human interaction partners of COG1 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

5 partners by confidence:

Partner	Interaction type	MIscore	Records
COG4	physical association	0.560	2
CDC42	physical association	0.370	1
COG8	association	0.350	1
DSCAM	physical association	0.000	1
MTNR1A	physical association	0.000	1

BioGRID (150 interactions; top human partners by supporting records): COG3 (Affinity Capture-MS; 8 records), COG4 (Co-fractionation; 6 records), COG5 (Co-fractionation; 5 records), COG6 (Co-fractionation; 5 records), COG2 (Co-fractionation; 4 records), COG7 (Co-fractionation; 4 records), COG8 (Co-fractionation; 4 records), BSG (Affinity Capture-MS; 3 records), CD274 (Affinity Capture-MS; 3 records), PARP16 (Affinity Capture-MS; 3 records), SCN2B (Affinity Capture-MS; 3 records), COMMD8 (Affinity Capture-MS; 2 records), GOLGA2 (Proximity Label-MS; 2 records), OPRM1 (Affinity Capture-MS; 2 records), AKT1 (Affinity Capture-MS)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
COG1	“form complex”	“COG tethering complex”	binding

Protein complexes (CORUM) (4)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

4 complexes by size:

Complex	Subunits	Members
COG complex	8	COG2, COG3, COG4, COG5, COG6, COG7, COG8, COG1
COG1-COG8-COG2-COG3-COG4 subcomplex	5	COG1, COG2, COG3, COG4, COG8
COG1-COG8-COG5-COG6-COG7 subcomplex	5	COG1, COG5, COG6, COG7, COG8
COG1-COG8 subcomplex	2	COG1, COG8

Disease & clinical

Genetic variants

Variant evidence for COG1: 519 ClinVar records (21 pathogenic / likely pathogenic). Per-variant detail is on Sugi Variant.

ClinVar

519 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	14
Likely pathogenic	7
Uncertain significance	253
Likely benign	157
Benign	36

Top pathogenic / likely-pathogenic (15)

Showing the 15 best-reviewed of 21 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
3655	NM_018714.3(COG1):c.1070+5G>A	Pathogenic	criteria provided, multiple submitters, no conflicts	4
2195938	NM_018714.3(COG1):c.1006C>T (p.Arg336Ter)	Pathogenic	criteria provided, multiple submitters, no conflicts	2
1480682	NM_018714.3(COG1):c.1130del (p.Lys377fs)	Pathogenic	criteria provided, single submitter	1
2027635	NM_018714.3(COG1):c.2686C>T (p.Gln896Ter)	Pathogenic	criteria provided, single submitter	1
2028309	NM_018714.3(COG1):c.254dup (p.Tyr86fs)	Pathogenic	criteria provided, single submitter	1
2805911	NM_018714.3(COG1):c.1091del (p.Asn364fs)	Pathogenic	criteria provided, single submitter	1
3684462	NM_018714.3(COG1):c.1401dup (p.Glu468Ter)	Pathogenic	criteria provided, single submitter	1
3728028	NM_018714.3(COG1):c.2665del (p.Arg889fs)	Pathogenic	criteria provided, single submitter	1
3728286	NM_018714.3(COG1):c.2665_2666insCG (p.Arg889fs)	Pathogenic	criteria provided, single submitter	1
4710995	NM_018714.3(COG1):c.415C>T (p.Gln139Ter)	Pathogenic	criteria provided, single submitter	1
4740975	NM_018714.3(COG1):c.2626_2629dup (p.Gly877fs)	Pathogenic	criteria provided, single submitter	1
4764410	NM_018714.3(COG1):c.1717C>T (p.Gln573Ter)	Pathogenic	criteria provided, single submitter	1
4780564	NM_018714.3(COG1):c.1487del (p.Gly496fs)	Pathogenic	criteria provided, single submitter	1
450371	NM_018714.3(COG1):c.2084_2085insCCTGGTAATAAAATGAC (p.His695_Gly696insLeuValIleLysTer)	Likely pathogenic	criteria provided, single submitter	1
452106	NM_018714.3(COG1):c.1823del (p.Leu608fs)	Likely pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore COG1’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 32 predictions of 1,198):

Position(s)	Effect	Δscore	Sites
17:73193385–73193386	donor_loss	1.0000	5
17:73200564–73200565	acceptor_loss	1.0000	5
17:73200777–73200778	donor_loss	1.0000	4
17:73203794–73203795	donor_loss	1.0000	3
17:73206263–73206264	donor_loss	1.0000	2
17:73206674	acceptor_gain	1.0000
17:73196479	acceptor_gain	0.9900
17:73196752–73196753	donor_loss	0.9900	5
17:73197046	donor_gain	0.9900
17:73200022–73200023	donor_loss	0.9900	5

AlphaMissense

1,298 missense substitutions predicted likely pathogenic (of 6,395 scored), across 423 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M69	9	0.921	0.993
D853	8	0.977	0.991
F22	8	0.969	0.991
D850	8	0.969	0.993
F852	8	0.966	0.997
F911	8	0.952	0.996
D482	8	0.929	0.965
D812	8	0.924	0.976
D58	8	0.913	0.956
F273	8	0.906	0.973
F857	8	0.873	0.981
D64	8	0.851	0.936
D855	8	0.777	0.876
W476	7	0.973	0.997
W716	7	0.970	0.996
W354	7	0.941	0.996
W414	7	0.929	0.977
W489	7	0.922	0.981
W685	7	0.920	0.993
M51	7	0.917	0.970

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	5.96e-05
Head and Neck Squamous Cell Carcinoma (TCGA)	unfavorable	9.71e-05

Disease associations

OMIM: gene MIM:606973 | disease phenotypes: MIM:611209

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
COG1-congenital disorder of glycosylation	Definitive	Autosomal recessive	3

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

1 validity classifications:

Disease	Classification	Inheritance
COG1-congenital disorder of glycosylation	Moderate	AR

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (12 panels, 12 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

12 panels:

Panel	Rating
Congenital disorders of glycosylation	green
DDG2P	green
Fetal anomalies	green
Hereditary ataxia and cerebellar anomalies, childhood onset	green
Hypotonic infant	green
Intellectual disability	green
Leukodystrophy, childhood onset	green
Likely inborn error of metabolism	green
Paediatric disorders	green
Skeletal dysplasia	green
Undiagnosed metabolic disorders	green
Unexplained death in infancy and sudden unexplained death in childhood	green

Mondo (2): COG1-congenital disorder of glycosylation (MONDO:0012637), nephrotic syndrome (MONDO:0005377)

Orphanet (1): COG1-CDG (Orphanet:263508)

HPO phenotypes

showing 60 of 91 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000047	Hypospadias
HP:0000083	Renal insufficiency
HP:0000126	Hydronephrosis
HP:0000160	Narrow mouth
HP:0000162	Glossoptosis
HP:0000175	Cleft palate
HP:0000201	Pierre-Robin sequence
HP:0000218	High palate
HP:0000219	Thin upper lip vermilion
HP:0000252	Microcephaly
HP:0000253	Progressive microcephaly
HP:0000274	Small face
HP:0000316	Hypertelorism
HP:0000319	Smooth philtrum
HP:0000343	Long philtrum
HP:0000347	Micrognathia
HP:0000358	Posteriorly rotated ears
HP:0000369	Low-set ears
HP:0000402	Stenosis of the external auditory canal
HP:0000405	Conductive hearing impairment
HP:0000431	Wide nasal bridge
HP:0000463	Anteverted nares
HP:0000470	Short neck
HP:0000475	Broad neck
HP:0000494	Downslanted palpebral fissures
HP:0000520	Proptosis
HP:0000582	Upslanted palpebral fissure
HP:0000750	Delayed speech and language development
HP:0000902	Rib fusion
HP:0000938	Osteopenia
HP:0000954	Single transverse palmar crease
HP:0001103	Abnormal macular morphology
HP:0001252	Hypotonia
HP:0001256	Mild intellectual disability
HP:0001263	Global developmental delay
HP:0001272	Cerebellar atrophy
HP:0001290	Generalized hypotonia
HP:0001320	Cerebellar vermis hypoplasia
HP:0001433	Hepatosplenomegaly
HP:0001508	Failure to thrive
HP:0001511	Intrauterine growth retardation
HP:0001531	Failure to thrive in infancy
HP:0001712	Left ventricular hypertrophy
HP:0001762	Talipes equinovarus
HP:0001773	Short foot
HP:0001873	Thrombocytopenia
HP:0001902	Giant platelets
HP:0001903	Anemia
HP:0001999	Abnormal facial shape
HP:0002059	Cerebral atrophy
HP:0002092	Pulmonary arterial hypertension
HP:0002280	Enlarged cisterna magna
HP:0002342	Moderate intellectual disability
HP:0002673	Coxa valga
HP:0002719	Recurrent infections
HP:0002751	Kyphoscoliosis
HP:0002943	Thoracic scoliosis
HP:0003026	Short long bone

MeSH disease descriptors

2 disease descriptors:

Descriptor	Name	Tree numbers
D009404	Nephrotic Syndrome	C12.050.351.968.419.630.643; C12.200.777.419.630.643; C12.950.419.630.643
C535756	Congenital disorder of glycosylation, type 2G *(supp.)*

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105805 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

1 measured of 1 human assays (2 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5653589	KD	1440 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 4 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.41	Kd	3.9	nM	CHEMBL3752910
8.41	ED50	3.9	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 6 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148104: Binding affinity to human COG1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0039	uM

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	3
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
2,4,6-tribromophenol	decreases expression	1
bisphenol A	decreases expression	1
decabromobiphenyl ether	decreases expression	1
sodium arsenite	increases expression	1
tetrabromobisphenol A	increases expression	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	increases methylation	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Ivermectin	decreases expression	1
Smoke	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases expression	1
Asbestos, Crocidolite	decreases expression	1
Thapsigargin	increases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4012601	Binding	Binding affinity to COG1 in human INA-6 cells after 3 hrs by nanoLC-MS/MS method	Ugi Reaction-Derived α-Acyl Aminocarboxamides Bind to Phosphatidylinositol 3-Kinase-Related Kinases, Inhibit HSF1-Dependent Heat Shock Response, and Induce Apoptosis in Multiple Myeloma Cells. — *J Med Chem*

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A637	KMS-18	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00029224	Phase 4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	Phase 4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	Phase 4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	Phase 4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	Phase 4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	Phase 4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	Phase 4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	Phase 4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	Phase 4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	Phase 4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	Phase 4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	Phase 4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	Phase 4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	Phase 4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	Phase 4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	Phase 4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	Phase 4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	Phase 4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	Phase 4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	Phase 4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	Phase 4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	Phase 4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	Phase 4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	Phase 4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	Phase 4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	Phase 4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	Phase 4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	Phase 4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	Phase 4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	Phase 4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	Phase 4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	Phase 4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	Phase 4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	Phase 4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	Phase 4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	Phase 4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	Phase 4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	Phase 4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	Phase 4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	Phase 4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
NCT01673984	Phase 4	TERMINATED	GP Extended Action Triptorelin
NCT01753297	Phase 4	COMPLETED	A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
NCT01794793	Phase 4	COMPLETED	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
NCT01950871	Phase 4	TERMINATED	Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning
NCT01995513	Phase 4	COMPLETED	Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
NCT02102646	Phase 4	COMPLETED	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
NCT02116582	Phase 4	COMPLETED	A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
NCT02149628	Phase 4	COMPLETED	The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide
NCT02405858	Phase 4	COMPLETED	A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
NCT02441517	Phase 4	TERMINATED	A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
NCT02441894	Phase 4	COMPLETED	Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer
NCT02475057	Phase 4	COMPLETED	Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
NCT02511665	Phase 4	UNKNOWN	Metformin And Longevity
NCT02651948	Phase 4	COMPLETED	Transperineal, MRI-guided, Prostate Biopsy
NCT02721433	Phase 4	COMPLETED	4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
NCT02726009	Phase 4	COMPLETED	A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
NCT02749825	Phase 4	TERMINATED	Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
NCT02757365	Phase 4	UNKNOWN	Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
NCT02773251	Phase 4	COMPLETED	The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery
NCT02812186	Phase 4	COMPLETED	Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for COG1 across ~30M SureChEMBL compounds — explore on Sugi Predict.